Stock AADI AADI BIOSCIENCE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Aadi Bioscience, Inc.

Equities

AADI

US00032Q1040

Market Closed - Nasdaq
Other stock markets
 21:00:00 08/05/2024 BST 		5-day change 1st Jan Change
1.84 USD -12.80% Intraday chart for Aadi Bioscience, Inc. -5.15% -8.91%
05-08 Earnings Flash (AADI) AADI BIOSCIENCE Reports Q1 Revenue $5.4M MT
05-08 Transcript : Aadi Bioscience, Inc., Q1 2024 Earnings Call, May 08, 2024

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Earnings Flash (AADI) AADI BIOSCIENCE Reports Q1 Revenue $5.4M
MT
Earnings Flash (AADI) AADI BIOSCIENCE Posts Q4 Revenue $6.3M
MT
Aadi Bioscience, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
North American Morning Briefing : Stock Futures -2-
DJ
Aadi Bioscience, Inc. Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations
CI
Aadi Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Earnings Flash (AADI) AADI BIOSCIENCE Reports Q3 Revenue $6M
MT
Aadi Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Earnings Flash (AADI) AADI BIOSCIENCE Reports Q2 Revenue $6.2M, vs. Street Est of $6.3M
MT
Earnings Flash (AADI) AADI BIOSCIENCE Reports Q1 Revenue $5.9M
MT
Aadi Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Aadi Bioscience, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
CI
Aadi Bioscience, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
CI
Earnings Flash (AADI) AADI BIOSCIENCE Posts Q4 Revenue $5.2M
MT
Aadi Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Earnings Flash (AADI) AADI BIOSCIENCE Reports Q3 Revenue $4.2M
MT
Earnings Flash (AADI) AADI BIOSCIENCE Reports Q3 Revenue $4.2M
MT
Mirati Therapeutics, Aadi Bioscience Team Up to Study Lung Cancer Combination Treatment
MT
Aadi Bioscience, Inc. Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-Sirolimus at 34th EORTC-NCI-AACR Symposium
CI
Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AADI Stock
  4. News Aadi Bioscience, Inc.
  5. Highlights